Investigating the link between sleep apnea and cognitive decline in older adults
Exploring the Association Between Cognitive Function, Obstructive Sleep Apnea and Brain Imaging, and the Determinants of Neurocognitive Decline in Subjects With Subjective or Mild Cognitive Impairment
The University of Hong Kong · NCT06150352
This study is testing if treating sleep apnea with a CPAP machine can help older adults with mild memory problems maintain their thinking skills.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Sponsor | The University of Hong Kong (other) |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06150352 on ClinicalTrials.gov |
What this trial studies
This observational study examines the relationship between obstructive sleep apnea (OSA) and neurocognitive decline in individuals aged 50 to 80 with mild cognitive impairment or subjective cognitive complaints. It aims to determine if OSA is a contributing factor to cognitive decline and whether treatment with Continuous Positive Airway Pressure (CPAP) can mitigate this decline. Participants will undergo baseline PET-MRI brain scans to assess amyloid accumulation and neurocognitive status. The study seeks to identify modifiable factors that could improve cognitive function in affected individuals.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 50 to 80 with mild cognitive impairment or subjective cognitive complaints who can read and speak Chinese.
Not a fit: Patients with diagnosed psychiatric illnesses or other clear organic causes of cognitive impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved cognitive outcomes for patients with mild cognitive impairment through targeted treatment of sleep apnea.
How similar studies have performed: Previous studies have suggested a link between sleep apnea and cognitive decline, indicating that this approach has potential but may still be novel in its specific focus.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 50 - 80 years * Diagnosis of mild cognitive impairment based on Peterson's criteria. * Diagnosis of subjective cognitive impairment, based on the subjective complaint of cognitive impairment, but with an unremarkable assessment of the Hong Kong version of Montreal cognitive Assessment scores * Able to speak and read Chinese * Adequate visual and auditory to perform a cognitive test * Subjects with moderate-severe OSA or No OSA (diagnosis based on sleep study) would be invited for baseline PET-MRI brain scan Exclusion Criteria: * Diagnosed psychiatric illness with or without medication, e.g. major depressive disorder. * Other clear organic causes of cognitive impairment, e.g. vascular cognitive impairment, brain tumour, dementia with Lewy body, mild cognitive impairment with Lewy body, Parkinson's disease, normal pressure hydrocephalus, neurosyphilis, autoimmune encephalitis, substance abuse, history of alcohol abuse. * Diagnosis of cancer on active treatment * Contraindications to PET-CT or MRI brain scan (excluded for neuroimaging studies)
Where this trial is running
Hong Kong
- Queen Mary Hospital — Hong Kong, Hong Kong (RECRUITING)
Study contacts
- Principal investigator: Mary SM Ip, MD — School of Clinical Medicine, The University of Hong Kong
- Study coordinator: Sau Man Mary Ip, MD
- Email: msmip@hku.hk
- Phone: 2255 5885
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Obstructive Sleep Apnea, Mild Cognitive Impairment, Subjective Cognitive Impairment, Obstructive sleep apnea, Neurocognitive function, CPAP